Patrick Cox

Soviet dictator Joseph Stalin is reported to have once said, “The death of one man is a tragedy, but the death of millions is a statistic.” Human psychology being what it is, we are shocked and appalled by the unusual, but we become habituated to what’s common, even if it’s something very bad.

In few places is this as true as in our reaction to disease. Something that regularly kills a great many people usually doesn’t elicit much of an emotional response. One good example is influenza. We tend to think of influenza, also known as “the flu,” as a common seasonal illness. Infecting up to one in five individuals during a typical year, it certainly qualifies as such. However, despite (or perhaps because of) the ubiquity of the influenza virus, it’s easy to forget what a huge problem it is.

Even during an average year, the influenza virus, in all of its various types and strains, hospitalizes 200,000 and kills some 40,000 people in the U.S. That’s a greater number than those generated by far more dreaded viruses like HIV and hepatitis C. In fact, influenza viruses kill more than HIV and hep C combined.

Worldwide, influenza’s death toll is even more shocking: It’s a safe bet that about half a million people will die of flu infections this year. To give that number some perspective, it’s more than the population of a major city like Miami… each and every year.

The economic toll is correspondingly large. Just in adults, influenza imposes an economic burden of $83 billion per year in the U.S.

Again, to give that number meaning, it’s more than the annual budget for a large state like Florida.

What’s worse about the cost of influenza is that these are typical yearly figures. These numbers aren’t representative of pandemic years — years when a particularly deadly and infectious strain of the virus breaks out. The cost in lives during those years can be far worse. The 1918 “Spanish flu” epidemic, for example, claimed upward of 50 million lives before it ran its course.

Influenza strains, even highly virulent ones, eventually peter out because our immune systems can adapt and defend us. Flu viruses, however, have a high mutation rate. New strains constantly emerge to which we haven’t developed immunity.

Furthermore, influenza is present not only in humans, but also in other animals like birds and pigs. Sometimes, a virus can jump between species or combine its genes with a human-specific version, creating a deadly and highly infectious new variety.

If you’ve read the headlines lately, you know this could be happening right now. Thousands of dead pigs have been mysteriously appearing in Chinese rivers, and people in that part of the world have begun dying of new flu outbreaks.

But that’s not all that’s worrisome. Just as troublesome are news reports of Chinese researchers creating new “hybrid flus.” These strains combine the genes of flu viruses present in several species. They could not only be transmittable to humans, but be highly deadly as well.

Although these Chinese virologists have been creating hybrid strains for benign reasons — to anticipate and prepare for the prospect of man-to-man transmission of these threatening strains — this might not always be the case in other places. Others could use the same methods to create deadly biological weapons. The danger of maliciously modified viruses is so great, in fact, that some experts consider it to be greater than the threat of nuclear terrorism.

Whether from natural or human causes, the next virus pandemic will, sooner or later, hit the globe. Fortunately, the science to counter these threats is maturing rapidly. Innovators are developing prophylactic and therapeutic biotechnology right now to address not only the risk of a deadly pandemic outbreak, but also the much-ignored, but still heavy toll of common seasonal influenza.

Yours for transformational profits,

Patrick Cox

You May Also Like:


Killing the Pain in Your Portfolio

Ray Blanco

One of the most important aspects of medical science is developing useful and effective pain medication. But at this point in human history, every advancement in this field has comes with its own set of drawbacks. Today, Ray Blanco explores this problem, and how some biotech companies are trying to fix it. Read on...

Patrick Cox

Patrick Cox has lived deep inside the world of transformative technologies for over 25 years. This expertise lead him to Mauldin Economics, where he now heads Transformational Technology Alert.

Recent Articles

How to Bag Easy Gains from the “Mass Affluent”

Greg Guenthner

But these mass affluent sorts have the loyalty of a hooker. They'll dump one high-end brand for another at the first whiff of a better deal. And a company's profits can go poof if it doesn't figure out in advance what the hell this bunch wants next season.


Addison Wiggin
When Genius Fails Again, Part III

Addison Wiggin

Addison Wiggin gives even more reasons why genius will fail again in part III of his series on Jim Rickards and the collapse of the financial market house of cards...


Beginning to Taste the Fountain of Youth

Stephen Petranek

It is well known that the longer you live, the more likely you are to develop heart disease, stroke, osteoporosis and Alzheimer’s, to list only a few. But research out of the Salk Institute may be the clearest, most direct leap in understanding aging in the history of medical research and opens extraordinary possibilities for slowing down or even halting the aging process in humans. Stephen Petranek has more…


How to Profit from the Death of a Chicken Empire

Greg Guenthner

American's tastes are evolving. McDonalds is out. Shake Shack and Chipotle are in. Consumers are willing to pay a premium price for better food. And investors are willing to pay a premium for better fast food's stock. It's that simple.